TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05601661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active VNS
Description: An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used. An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) . All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc. The device is programmed to stimulate for 0.5s on each button push. After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0.8 mA)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VNS
Description: An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used. An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) . All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc. The device is programmed to stimulate for 0.5s on each button push. After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0 mA)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Arm rehabilitation
Description: . The rehabilitation therapy involves arm and hand exercises with objects. The therapist will select these exercises based on movement abilities. Tasks will be selected from six functional task categories: reach and grasp, gross movement, object flipping, simulated eating tasks, inserting objects, and opening containers. Approximately 30-50 repetitions will be performed in each category. On average, 300-500 repetitions will be performed during each session within 1.5-2hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm rehabilitation
Description: . The rehabilitation therapy involves arm and hand exercises with objects. The therapist will select these exercises based on movement abilities. Tasks will be selected from six functional task categories: reach and grasp, gross movement, object flipping, simulated eating tasks, inserting objects, and opening containers. Approximately 30-50 repetitions will be performed in each category. On average, 300-500 repetitions will be performed during each session within 1.5-2hours.
Study: NCT05092685

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAVLK03hOTC
Description: Peripheral intravenous infusion of AAVLK03hOTC.
Study: NCT05087147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.7 mm stainless steel orthodontic wire
Description: 0.7 mm stainless steel orthodontic wire

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Banded space maintainer
Description: band and loop space maintainer
Study: NCT00967759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronpheniramine and fenilefrine (Decongex Plus)
Description: Oral Solution: Bronpheniramine (2mg/ml) and fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronpheniramine isolated
Description: Oral Solution: Bronpheniramine (2mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
Study: NCT05318183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Wheat Bread
Description: Standardized whole wheat bread (128 g daily)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White Bread (control)
Description: Standardized white bread (128 g daily)
Study: NCT05548842

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill
Description: The combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill 1,000 mg/day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo 1,000 mg/day for 4 weeks
Study: NCT04754737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No antibiotic
Description: No antibiotics will be given prior to intravesical injection of onabotulinumtoxinA

Intervention type: OTHER
Group type: OTHER
Intervention: Prophylactic antibiotic
Description: This is the current standard of care, this group of patients will be given a single dose of prophylactic antibiotic prior to the injection of onabotulinumtoxinA via cystoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cystoscopic injection of onabotulinumtoxinA
Description: cystoscopic injection of onabotulinumtoxinA

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cystoscopic injection of onabotulinumtoxinA
Description: cystoscopic injection of onabotulinumtoxinA
Study: NCT06389747

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BFR technique
Description: For BFR application, Airbands brand, wireless, automatic training cuffs will be used. During application, it will be ensured that the device module faces forward and the cuff will be fixed in the correct position by wrapping the band around the metal ring. There will be a space between the skin and the cuff that can fit two fingers. The cuff will then be paired via Bluetooth with the Airbands app installed on the phone. BFR cuffs will be placed proximal to the biceps brachii muscle and pressure will be applied. The cuff will be inflated to automatically detect limb pressure. BFR application with 80% pressure to one group of participants and 20% pressure to the other group will be applied simultaneously with the exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BFR technique
Description: For BFR application, Airbands brand, wireless, automatic training cuffs will be used. During application, it will be ensured that the device module faces forward and the cuff will be fixed in the correct position by wrapping the band around the metal ring. There will be a space between the skin and the cuff that can fit two fingers. The cuff will then be paired via Bluetooth with the Airbands app installed on the phone. BFR cuffs will be placed proximal to the biceps brachii muscle and pressure will be applied. The cuff will be inflated to automatically detect limb pressure. BFR application with 80% pressure to one group of participants and 20% pressure to the other group will be applied simultaneously with the exercise.
Study: NCT00967759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenilefrine isolated
Description: Oral Solution: Fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
Study: NCT05687006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colour Doppler Ultrasound
Description: The main perforators were examined using a LOGIQ S8/V1 CDU device (GE Healthcare, Chalfont St Giles, Great Britain) with a linear transducer of frequency 4-11 MHz. Measured parameters were: 1) calibre of artery and vein; 2) Peak systolic velocity (PSV) of blood in the artery \[cm/s\]; 3) blood velocity in the perforator vein \[cm/s\]; 2) the thickness of the subcutaneous tissue of the lower abdomen measured 4 cm caudal and lateral to the umbilicus. Any additional perforators were marked nor have CTA deducted XY coordinates of marked perforators changed based on the CDU examination. The same sonography surgeon performed all CDU examinations. The time duration of the CDU examination was measured.
Study: NCT05671796

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell transplantation
Description: Patients will undergo two autologous bone marrow stem cell transplantation into the lesion area

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will undergo two subcutaneous injections of 1 ml of glycophysiological solution into the lesion area by sham procedure
Study: NCT04920968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland. Patients in experimental arm will receive obinutuzumab .Obinutuzumab: 1000 mg i.v. (first infusion divided into 100 mg on d. 1 and 900 mg on d. 2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland.The protocol includes the use of rituximab in combination chemotherapy. Rituximab: 375 mg/m2 intravenously (i.v.)
Study: NCT04842006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total neoadjuvant therapy (TNT)
Description: Short radiotherapy (5X5 Gy) and capecitabine/oxaliplatin

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Minimal residual disease (MRD)
Description: Postoperative MRD on circulating cell-free DNA

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Long radiation therapy
Description: Long-course 50.4 Gy radiation with capecitabine
Study: NCT06244563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face mask with Hybrid-Hyrax
Description: Participants were treated with face mask using a Hybrid-Hyrax appliance as an anchor in the maxillary arch. The anchorage of hybrid-hyrax appliance was provided by bands adapted to the maxillary first permanent molars and two mini screws in the anterior palate. Force transmission was achieved using intermaxillary elastics that were connected to the face mask arms from the hooks of the hybrid-hyrax appliance in the maxillary canine region.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face mask with Hybrid-Hyrax
Description: Participants were treated with face mask using a Hybrid-Hyrax appliance as an anchor in the maxillary arch. The anchorage of hybrid-hyrax appliance was provided by bands adapted to the maxillary first permanent molars and two mini screws in the anterior palate. Force transmission was achieved using intermaxillary elastics that were connected to the face mask arms from the hooks of the hybrid-hyrax appliance in the maxillary canine region.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face mask with Bonded RME
Description: Participants were treated with face mask using a bonded RME appliance as an anchor in the maxillary arch. The anchorage of bonded RME appliance was provided by maxillary posterior teeth covered with acrylic cap. Force transmission was achieved using intermaxillary elastics that were connected to the face mask arms from the hooks of the bonded RME in the maxillary canine region.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face mask with Bonded RME
Description: Participants were treated with face mask using a bonded RME appliance as an anchor in the maxillary arch. The anchorage of bonded RME appliance was provided by maxillary posterior teeth covered with acrylic cap. Force transmission was achieved using intermaxillary elastics that were connected to the face mask arms from the hooks of the bonded RME in the maxillary canine region.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alternative Rapid Maxillary Expansion and Contraction Protocol (Alt-RAMEC)
Description: In the groups that started with the Alt-Ramec protocol, the parents expanded the appliance screw twice a day in the first week and closed it in the opposite direction in the following week. This process was continued for 7-9 weeks according to the patient's need for expansion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alternative Rapid Maxillary Expansion and Contraction Protocol (Alt-RAMEC)
Description: In the groups that started with the Alt-Ramec protocol, the parents expanded the appliance screw twice a day in the first week and closed it in the opposite direction in the following week. This process was continued for 7-9 weeks according to the patient's need for expansion.
Study: NCT05023148

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Description: Stimulating acupoints using electric stimulator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thread embedded acupuncture
Description: Stimulating acupoints using thread embedded
Study: NCT06244563

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine Rapid Maxillary Expansion Protocol
Description: In the groups that started with the routine protocol, parents activated the expansion screw twice a day for 1-2 weeks, depending on the patient's need for expansion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine Rapid Maxillary Expansion Protocol
Description: In the groups that started with the routine protocol, parents activated the expansion screw twice a day for 1-2 weeks, depending on the patient's need for expansion.
Study: NCT04874090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Investigator will apply the acupuncture treatment to the first group to the neck area. BL-15, BL-18, BL-23, BL-25, KB-4, Du-20, GB-20, CV-14, KB-10, Ex-26, Yin Tang, Ah-shi points will be used. 0.25x25 mm, sterile, steel, disposable, acupuncture needle will be used for acupuncture points and painful trigger points. The treatment will be applied twice a week, on average 10 sessions. Dry needling treatment will be applied to the patients by a certified physician. All patient will be performed the neck exercises program

Intervention type: OTHER
Group type: OTHER
Intervention: Exercises
Description: Patient will perform neck exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Patient will perform neck exercises
Study: NCT04957758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-01 (varenicline) nasal spray 1.2 mg/ml
Description: OC-01

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle) nasal spray
Description: Placebo (vehicle)
Study: NCT05041348

Intervention type: DIAGNOSTIC_TEST
Intervention: CT at the level of the third lumbar vertebra (L3)
Description: Muscle mass loss was defined as an skeletal muscle mass index (SMI) less than 46.96 cm²/m² for males and less than 32.46 cm²/m² for females

Intervention type: DIAGNOSTIC_TEST
Intervention: CT at the level of the third lumbar vertebra (L3)
Description: Muscle mass loss was defined as an skeletal muscle mass index (SMI) less than 46.96 cm²/m² for males and less than 32.46 cm²/m² for females
Study: NCT06505486

Intervention type: DRUG
Intervention: Gemcitabine-Oxaliplatin Regimen
Description: Hepatic arterial infusion chemotherapy (HAIC) of gemcitabine and oxaliplatin (GEMOX) plus systemic gemcitabine chemotherapy (GEM-SYS) combined with lenvatinib and programmed cell death protein-1 (PD-1) inhibitor.
Study: NCT06398717

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block
Description: group C will receive a unilateral adductor canal block alone, using an ultrasound to identify the location of the nerve.~group H will receive unilateral peri-hamstring injection combined to adductor canal block, After the adductor canal block, the transducer will be moved posteriorly till identifying the site of injection group O will receive unilateral anterior obturator nerve block combined with adductor canal block, The anterior branch of the obturator nerve is located using ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block
Description: group C will receive a unilateral adductor canal block alone, using an ultrasound to identify the location of the nerve.~group H will receive unilateral peri-hamstring injection combined to adductor canal block, After the adductor canal block, the transducer will be moved posteriorly till identifying the site of injection group O will receive unilateral anterior obturator nerve block combined with adductor canal block, The anterior branch of the obturator nerve is located using ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block
Description: group C will receive a unilateral adductor canal block alone, using an ultrasound to identify the location of the nerve.~group H will receive unilateral peri-hamstring injection combined to adductor canal block, After the adductor canal block, the transducer will be moved posteriorly till identifying the site of injection group O will receive unilateral anterior obturator nerve block combined with adductor canal block, The anterior branch of the obturator nerve is located using ultrasound
Study: NCT05956509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABBV-950
Description: Intramuscular (IM) Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABBV-950
Description: Intramuscular (IM) Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABBV-950
Description: Intramuscular (IM) Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABBV-950
Description: Intramuscular (IM) Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABBV-950
Description: Intramuscular (IM) Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABBV-950
Description: Intramuscular (IM) Injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX
Description: Intramuscular (IM) Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-950
Description: Intramuscular (IM) Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-950
Description: Intramuscular (IM) Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-950
Description: Intramuscular (IM) Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-950
Description: Intramuscular (IM) Injection
Study: NCT05894733

Intervention type: OTHER
Group type: OTHER
Intervention: study group
Description: Calling with phone frequently(15.th day, 1 month , 3 month, 6 month ) and face to face interwiew on first, 3 th and 6th month

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: first and sixth month face to face interwiew
Study: NCT05552677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent Training
Description: Participants will perform a multicomponent training that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 12 weeks
Study: NCT04415281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THOR® laser system
Description: We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham THOR® laser system
Description: sham THOR® laser system
Study: NCT05764174

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Factual messages
Description: Messages with descriptive data on COVID-19 vaccines

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Narrative message
Description: Messages with emotional descriptions on COVID-19 vaccines

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mixed message
Description: Messages with both descriptive data and emotional descriptions on COVID-19 vaccines
Study: NCT04778800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: almonertinib
Description: Patients was given a standard dose of 110mg/day of almonertinib, orally, and the first efficacy evaluation was carried out 4 weeks later. If the patient's lungs and/or other parts of the disease (PD) progress, then leave the group to receive other treatment; if the patient's lungs If the brain and other parts are stable or relieved and the brain has not progressed, continue the original dose treatment, and evaluate the effect every 8 weeks. Until the patient's lungs and/or other parts progress (PD), then leave the group to receive other treatment; if If the patient's lungs and other parts are stable or relieved and the brain is progressing, the dose of almonertinib can be increased to 165mg/day, orally ± radiotherapy (the investigator's decision), and then the efficacy will be evaluated every 8 weeks until the patient's lungs and/ Or there is progress (PD) in other parts, then the group will receive other treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-first line treatment
Description: Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-second line treatment
Description: Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.